文献速递冠心病血脂与心血管预防

脂蛋白(a)水平与低衰减斑块患者心肌梗死的关联

Association of Lipoprotein(a) Levels With Myocardial Infarction in Patients With Low-Attenuation Plaque.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

这项多中心研究纳入衍生队列5607例接受CCTA和Lp(a)检测的稳定胸痛疑似冠心病患者,并回顾性收集验证队列1122例。中位随访8.2年显示,高Lp(a)(≥50 mg/dL)与心梗风险相关(aHR 1.91),且与低衰减斑块存在显著交互作用,LAP介导了73.3%的关联。

要点

  • 高Lp(a)(≥50 mg/dL)与心梗风险独立相关,aHR为1.91。
  • Lp(a)与低衰减斑块对心梗风险存在显著交互作用(P<0.001)。
  • 有低衰减斑块者中Lp(a)与心梗关联更强,aHR为3.03。

核心结论

  • 高Lp(a)水平在8年随访中增加心梗风险,尤其在CCTA识别的低衰减斑块患者中更为显著。
  • 低衰减斑块的存在可强化Lp(a)与未来心梗发生的关联。

研究设计与样本

  • 多中心研究,衍生队列前瞻性纳入5607例接受CCTA和Lp(a)检测的稳定胸痛疑似冠心病患者。
  • 验证队列回顾性收集同期1122例患者。
  • 高Lp(a)定义为Lp(a) ≥50 mg/dL,主要终点为致死性或非致死性心梗复合终点。

主要发现

  • 中位随访8.2年(Q1-Q3:7.2-9.3年),高Lp(a)与心梗风险相关(aHR:1.91;95%CI:1.46-2.49;P<0.001)。
  • Lp(a)与低衰减斑块对心梗风险存在显著交互作用(Pinteraction<0.001)。
  • 有低衰减斑块患者中,Lp(a)与心梗相关(aHR:3.03;95%CI:1.92-4.76;P<0.001)。
  • 中介分析显示低衰减斑块介导了Lp(a)与心梗关系的73.3%(P<0.001)。
  • 主要发现在验证队列中保持不变。

关键数值与推荐

  • 高Lp(a)定义为Lp(a) ≥50 mg/dL。
  • 主要终点为致死性或非致死性心梗复合终点。

临床怎么用

  • 对稳定胸痛疑似冠心病患者,可结合Lp(a)水平与CCTA低衰减斑块评估心梗风险。
  • 低衰减斑块患者中Lp(a)升高提示心梗风险进一步增加,可能需更积极管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lipoprotein(a) (Lp[a]) is associated with an increased risk of myocardial infarction (MI). However, the mechanism underlying this association has yet to be fully elucidated. OBJECTIVES: This multicenter study aimed to investigate whether association between Lp(a) and MI risk is reinforced by the presence of low-attenuation plaque (LAP) identified by coronary computed tomography angiography (CCTA). METHODS: In a derivation cohort, a total of 5,607 patients with stable chest pain suspected of coronary artery disease who underwent CCTA and Lp(a) measurement were prospectively enrolled. In validation cohort, 1,122 patients were retrospectively collected during the same period. High Lp(a) was defined as Lp(a) ≥50 mg/dL. The primary endpoint was a composite of time to fatal or nonfatal MI. Associations were estimated using multivariable Cox proportional hazard models. RESULTS: During a median follow-up of 8.2 years (Q1-Q3: 7.2-9.3 years), the elevated Lp(a) levels were associated with MI risk (adjusted HR [aHR]: 1.91; 95% CI: 1.46-2.49; P < 0.001). There was a significant interaction between Lp(a) and LAP (Pinteraction <0.001) in relation to MI risk. When stratified by the presence or absence of LAP, Lp(a) was associated with MI in patients with LAP (aHR: 3.03; 95% CI: 1.92-4.76; P < 0.001). Mediation analysis revealed that LAP mediated 73.3% (P < 0.001) for the relationship between Lp(a) and MI. The principal findings remained unchanged in the validation cohort. CONCLUSIONS: Elevated Lp(a) augmented the risk of MI during 8 years of follow-up, especially in patients with LAP identified by CCTA. The presence of LAP could reinforce the relationship between Lp(a) and future MI occurrence.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Yu MM, Wang ML, Wang JJ, et al. Association of Lipoprotein(a) Levels With Myocardial Infarction in Patients With Low-Attenuation Plaque. J Am Coll Cardiol. 2024. PMID: 38692827. doi:10.1016/j.jacc.2024.03.367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。